Donanemab Slows Decline of Early Alzheimer’s

Donanemab Slows Decline of Early Alzheimer’s

Eli Lilly and Company announced positive results of the TRAILBLAZER-ALZ 2 Phase 3 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease. Donanemab met the primary endpoint of...